Clay Siegall is the CEO, chairman, and co-founder of Seattle Genetics. The company joined the medical business market in 1998. The discovery of Seattle Genetics was as a result of a passion for helping patients with recurring diseases and an innovative biotechnological research. The firm has many licenses one of them being the Pfizer. Currently, Seattle Genetics has made more than $1.3 billion via diverse modes of funding. The company has also earned the current funds they have by teaming up with other biotechnological firms.
In the early 1990’s, Dr. Siegall worked for many institutions including the National Cancer Institute and the National Institutes of Health. He has won numerous accolades, including the Young Entrepreneur of the Year and the 2012 Pacific Northwest Ernst. Mr. Clay Siegall is a Genetics Ph.D. holder from the University of George Washington.
Media houses who have Featured Dr. Siegall
In May 2015, Dr. Siegall did an interview with The Seaport World Trade Center’s Pegs Boston about the future that he perceives for ADCETRIS (ADC) drug that is designed to assist in hindering a relapse complication that arises from post-transplants and also the future of Seattle Genetics in the medicine world. Seattle Genetics had a couple of other approved drugs like the SGN-CD19A and SGN-CD33A. SGN-CD33A is modified to medicate leukemia cells while SGN-CD19A is used to stabilize the bloodstream to allow the cytotoxic agents excretion out the blood system.
In the month of September 2016, Hackryonm published a report that claimed that Dr. Siegall, CEO of Seattle Genetics got an approval stamp from FDA. This approval occurred after Seattle Genetics established a number of cancer antibodies that do not only heal the blood-related disease on the surface but also acts as a curing therapy. The post went on to say that Seattle Genetics can also treat cancer and oter autoimmune illnesses like lupus.
Under Dr. Siegall’s tenure, Seattle Genetics came up with different antibody-based cancer therapies. These drugs include the likes of brentuximab vedotin which is also known as ADCETRIS that got approval by the United States Food and Drug Administration (FDA) in 2011.
Dr. Siegall also guided Seattle Genetics fundraising programs in coming up with $675 million via private and public financing.